Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870731 | 0.79 | GRM4 (0.40) | MAPTBRD4HTR2AGRM4 | |
| SCHEMBL17870808 | 0.79 | CYP17A1 (0.37) | BRD4HTR2A | |
| SCHEMBL19873784 | 0.79 | GNRHR (0.39) | MAPTHTR2AGNRHR | |
| SCHEMBL30178497 | 0.79 | GNRHR (0.39) | MAPTHTR2AGNRHR | |
| SCHEMBL15538152 | 0.78 | BRD4 (0.46) | METMAPTBRD4HTR2A | |
| SCHEMBL19873895 | 0.77 | HTR2A (0.34) | METMAPTBRD4HTR2A | |
| SCHEMBL19873692 | 0.75 | HTR2A (0.37) | METMAPTHTR2A | |
| SCHEMBL19873779 | 0.71 | GAA (0.53) | MAPTBRD4HTR2A | |
| SCHEMBL19873892 | 0.71 | MAPT (0.33) | MAPTHTR2A | |
| SCHEMBL17870828 | 0.70 | BACE1 (0.37) | MAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3708566-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2020-09-16 | — | — | EP | disclosed |
| EP-3237403-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2020-05-06 | — | — | EP | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
| EP-3237403-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102882-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | VHL 1631/4885MET 3272/4885FEN1 4125/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | VHL 1643/4885MET 3244/4885FEN1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.